Tolerogenic anti–IL-2 mAb (JES6-1A12) and TAC induce distinct T-cell subpopulations and T-cell transcriptional signatures. (A) t-SNE plot displaying clusters identified in spleen cells from recipients treated with anti–IL-2 mAb (JES6-1A12) or TAC on day 7 after HCT. (B) Violin plots showing CD3e, CD4, and CD8a distribution on individual clusters. (C) Violin plot showing Tcf7 expression level in individual clusters under anti–IL-2 mAb (JES6-1A12) or TAC treatment. (D) Compared T-cell percentage in individual clusters under anti–IL-2 mAb (JES6-1A12) or TAC treatment.